Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain

Abstract

Radiotherapy is commonly used to treat cancer patients. Besides the curable effect, radiotherapy also could relieve the pain of cancer patients. However, cancer pain is gradually alleviated about two weeks after radiotherapy. In addition, cancer patients who receive radiotherapy may also suffer from pain flare or radiotherapy-induced side effects such as radiation esophagitis, enteritis, and mucositis. Pain control is reported to be inadequate during the whole course of radiotherapy (before, during, and after radiotherapy), and quality of life is seriously affected. Hence, radiotherapy is suggested to be combined with analgesic drugs in clinical guidelines. Previous studies have shown that radiotherapy combined with oxycodone hydrochloride can effectively alleviate cancer pain. In this review, we firstly presented the necessity of analgesia during the whole course of radiotherapy. We also sketched the role of oxycodone hydrochloride in radiotherapy of bone metastases and radiotherapy-induced oral mucositis. Finally, we concluded that oxycodone hydrochloride shows good efficacy and tolerance and could be used for pain management before, during, and after radiotherapy.

Evaluation of the clinical efficacy of oxycodone PCIA in patients with postherpetic neuralgia complicated with breakthrough pain: protocol for a prospective, double-blind, randomized controlled trial

“…Oxycodone is a semi-synthetic opioid drug made from thebaine plant derivatives, which is a strong opioid analgesic and a pure opioid dual-receptor agonist, mainly acting on μ opioid receptors and κ opioid receptors in the central nervous system and smooth muscle to produce analgesia, and is widely used in the treatment of moderate and severe acute and chronic pain and cancer pain [9]. Previous studies [10] on cancer pain have found that oxycodone has similar e cacy as rst-line drug morphine for moderate to severe cancer pain, but it has fewer adverse reactions than morphine: Gastrointestinal reactions such as nausea, vomiting and constipation are relieved; The risk of drug dependence and drug abuse is reduced, and it is less likely to cause side effects such as mental euphoria and respiratory depression; Morphine is prone to drug resistance and needs to continuously increase the dose, and even signi cant hyperalgesia occurs in severe cases; Strong opioids such as morphine and fentanyl reduce T cells and have immunosuppressive effects, but oxycodone has weaker immunosuppressive effects than morphine. This is due to the fact that oxycodone acts through dual opioid receptors and has a stronger binding force to κ receptors, and its analgesic effect is mainly achieved through κ receptors.…”

Projection into the future: combination of orphenadrine and diclofenac in patients with bone metastases

“…Радиационное облучение запускает воспалительную реакцию в костной мишени, а воспалительный процесс, возникаю щий при этом, увеличивает продукцию провоспалительных цитокинов, хемокинов, ионов водорода и оксида азота в облученных тканях, что резко обостряет болевой сидром в месте метастаза [18], поэтому ЛТ взывает временное усиление интенсивности болевого синдрома [19][20][21]. Обострение боли представляет собой кратковременное усиление боли на 2 и более баллов по десятибалльной шкале оценки интенсивности болевого синдрома на фоне ранее подобранной анальгетической терапии после проведенной ЛТ, особенно после однократного облучения в высокой дозе [22][23][24]. Усиление интенсивности боли наблюдается примерно у 40% пациентов с костными метастазами, прошедшими курс паллиативной ЛТ [25].…”